HUTCHMED (HCM) Competitors

Blueprint Medicines (NASDAQ:BPMC) and HUTCHMED (NASDAQ:HCM) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.

Does the MarketBeat Community believe in BPMC or HCM?

Blueprint Medicines received 236 more outperform votes than HUTCHMED when rated by MarketBeat users. Likewise, 66.99% of users gave Blueprint Medicines an outperform vote while only 66.25% of users gave HUTCHMED an outperform vote.

Company	Underperform	Outperform
Blueprint Medicines	Outperform Votes 554 66.99%	Underperform Votes 273 33.01%
HUTCHMED	Outperform Votes 318 66.25%	Underperform Votes 162 33.75%

Which has better earnings & valuation, BPMC or HCM?

HUTCHMED has higher revenue and earnings than Blueprint Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$562.12M	14.70	-$67.09M	-$2.47	-51.81
HUTCHMED	$630.20M	4.74	$100.78M	N/A	N/A

Is BPMC or HCM more profitable?

HUTCHMED has a net margin of 0.00% compared to Blueprint Medicines' net margin of -13.19%. HUTCHMED's return on equity of 0.00% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-13.19%	-77.49%	-20.84%
HUTCHMED	N/A	N/A	N/A

Does the media refer more to BPMC or HCM?

In the previous week, Blueprint Medicines had 16 more articles in the media than HUTCHMED. MarketBeat recorded 23 mentions for Blueprint Medicines and 7 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.04 beat Blueprint Medicines' score of 0.41 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Blueprint Medicines	6 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
HUTCHMED	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals believe in BPMC or HCM?

8.8% of HUTCHMED shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has more risk and volatility, BPMC or HCM?

Blueprint Medicines has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Do analysts prefer BPMC or HCM?

Blueprint Medicines presently has a consensus target price of $129.35, suggesting a potential upside of 1.09%. HUTCHMED has a consensus target price of $19.00, suggesting a potential upside of 10.79%. Given HUTCHMED's higher possible upside, analysts clearly believe HUTCHMED is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	0 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32
HUTCHMED	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Blueprint Medicines beats HUTCHMED on 9 of the 17 factors compared between the two stocks.